Immuron Limited (IMRN)

Market Cap	11.02M +4.9%
Revenue (ttm)	5.34M +5.9%
Net Income	-2.66M
EPS	-0.01
Shares Out	322.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	89,820
Open	1.200
Previous Close	1.180
Day's Range	1.150 - 1.240
52-Week Range	0.677 - 2.390
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About IMRN

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive func...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: IMRN
• Website: https://www.immuron.com.au

Financial Performance

In fiscal year 2026, Immuron's revenue was 7.71 million, an increase of 5.85% compared to the previous year's 7.29 million. Losses were -3.84 million, -26.41% less than in 2025.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 19, 2026

Data Sources Report a data error